J A Sinkule

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.

John H. Rodman, Minnie Abromowitch, J A Sinkule et al. · Journal of Clinical Oncology · 1987 · 115 citations

Mean Css, Pathology, Pharmacotherapy +19

Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer

WilliamE. Evans, J A Sinkule, WilliamR. Crom et al. · Cancer Chemotherapy and Pharmacology · 1982 · 107 citations

Oncology, Medicine, Clinical Pharmacology +6

Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.

J A Sinkule, Paul R. Hutson, F. Ann Hayes et al. · PubMed · 1984 · 65 citations

Systemic Clearance, Oncology, Pharmacology +10

A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia.

Richard A. Larson, K Daly, Kyung Eob Choi et al. · Journal of Clinical Oncology · 1987 · 54 citations

Hematological Malignancy, Pharmacokinetic Modeling, Medicine +11

Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts.

Lois W. Dow, J A Sinkule, A. Thomas Look et al. · PubMed · 1983 · 44 citations

Immunotoxicology, Chemoprevention Strategy, Immunology +17